$1.32
-0.06-4.35%
At close: -
$1.23
-0.09-6.81%
After Hours: 4:55 PM EDT
Comments
Loading...
PharmaCyte Biotech Stock Guidance | NASDAQ:PMCB | Benzinga
PharmaCyte Biotech issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/11/2022 | PMCB | PharmaCyte Biotech | FY | 2022 | -$0.27 | -$0.27 | -$0.24 | — | — | — | Get Alert |
FAQ
What is the most recent guidance for PharmaCyte Biotech (PMCB)?
The most recent guidance for PharmaCyte Biotech (PMCB) was reported on July 11, 2022 for the full year 2022. The company provided earnings per share guidance in the range of $-0.27 to $-0.27, compared to the estimated EPS of $-0.24. Additionally, PharmaCyte Biotech forecasted revenue between $0.00B and $0.00B for the quarter.
Browse guidance and forecast on all stocks.